Kancera has entered into an agreement with Acturum Life Science AB in order to evaluate and further develop the unique Fractalkine inhibitor AZD8797. Published research points to that Fractalkine signaling probably contributes to the growth and spread of tumors...
Read MoreThe period January to June 2014 and the second quarter 2015 in brief R&D expenses for the period amounted to SEK 8.8m (SEK 6.9m) of which the second quarter constituted SEK 4.6m (SEK 3.4m). Operating income for the period...
Read MoreIn 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read MoreKancera reports results from the company's cancer project portfolio generated in 2015.
Read MoreIn 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read MoreKancera reports that a second efficacy study of the drug candidate KAN0439834 (small molecule inhibitor of ROR1) has been completed in an animal model of an advanced stage of chronic lymphocytic leukemia. The results show that KAN0439834 reduces the...
Read MoreKancera reports that an investigation of the mechanism of action of the company's patent-pending HDAC6 inhibitors has demonstrated a unique profile that could strengthen the competitiveness of the project.
Read MoreJanuary 1 - September 30, 2014. All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...
Read MoreKancera reports the results of an analysis of the preclinical efficacy study that was completed during the third quarter as reported in a press release on October 3, 2014. The results confirm that the number of cancer cells in...
Read MoreKancera reports that an initial efficacy study of KAN0439834 (a small molecule inhibitor of ROR1) has been completed in an animal model of chronic lymphocytic leukemia. Preliminary results show that KAN0439834 reduces the number of ROR-expressing leukemia cells after...
Read More